In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Effects of statins on inflammatory markers and matrix metalloproteinases in patients with ST-segment elevation myocardial infarction
1Research Institute for Complex Issues of Cardiov. Dis. - Siberian Branch RAMS Institution Scientific - Kemerovo - Russian Federation
On behalf: Pecherina T.B., Kashtalap V.V., Barbarash O.L.
Aim: To evaluate the effects of statins on inflammatory markers and MMP-1, MMP-3, and MMP-9 in patients with ST-segment elevation myocardial infarction. Materials and Methods: A prospective cohort study was conducted with 175 consecutive patients with STEMI. The mean age of all patients was 61.3 ± 8.4 years, of whom 116 (66.3%) were males and 59 (33.7%) were females. Serum concentrations of interleukin (IL-6, IL-10, IL-12), CRP, TNF-a and MMP-1, MMP-3, MMP-9 and blood lipid parameters were measured in all patients on days 1 and 12 of the onset of MI. All patients were enrolled into two groups: Group 1 (n=136 (77.71%) without statin therapy and Group 2 (n=39 (22.29%) with pre-hospital statin therapy. Results: Patients (n = 39) with statin use of at least 7 days prior to the onset of STEMI demonstrated significantly lower levels of LDL [2.91 (1.31; 5.13) vs 1.34 (0.76; 9.77]), compared to patients without statin therapy. However, there were no significant differences in the levels of total cholesterol, HDL and TG in both groups. After analyzing levels of studied biomarkers in both groups, significantly lower levels of inflammatory markers (IL-6, CRP, TNF-a), and MMP-9 on days 1 and 12 of STEMI in patients with pre-hospital statin therapy were found. There was a 2-fold increase of anti-inflammatory marker IL-10 in patients with pre-hospital statins, compared to patients without statins (Table 1). Conclusion: Pre-hospital statin therapy in patients STEMI is associated with lower levels of proinflammatory markers (IL-6, CRP, TNF-a), and MMP-9 in the in-hospital period.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease